AU Patent

AU2024201871B2 — Cancer treatment

Assigned to Janssen Pharmaceutica NV · Expires 2026-02-26 · 0y expired

What this patent protects

The present invention provides a method for the treatment of cancer with erdafitinib.

USPTO Abstract

The present invention provides a method for the treatment of cancer with erdafitinib.

Drugs covered by this patent

Balversa (ERDAFITINIB) · Johnson & Johnson

Patent Metadata

Patent number: AU2024201871B2
Jurisdiction: AU
Classification: —
Expires: 2026-02-26
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.